DOCSLIB.ORG

Dyslipidemia Sample

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dyslipidemia Sample DYSLIPIDEMIA Laura Waite, PharmD, BCPS, CLS, BC-ADM and Thaddeus McGiness, PharmD, BCPS Quick Facts Risk factors1 Complications5 00 Type 2 diabetes mellitus (T2DM): T2DM can Over time, high cholesterol levels can lead to the decrease levels of good cholesterol (HDL) following: and increase levels of bad cholesterol 00 Artery damage (LDL), which increases chance for a cardio- 00 Hardening of the arteries (atherosclerosis) vascular (CV) event, such as stroke. 00 Heart disease 00 Lifestyle choices: eating a diet high in 00 Increased risk of stroke saturated and trans fats, physical inactivity, 00 Chest pain caused by decreased lack of obesity oxygen-rich blood 00 Family history 00 Peripheral artery disease (PAD) caused by 00 Age: Risk increases with advancing age decreased blood flow to arteries in arms, 00 Gender: men typically have lower HDL stomach, legs, and feet levels than women; women typically have lower LDL levels than men (until age 55) REFERENCES 1. Centers for Disease Control. Knowing your risk: high Prevalence and incidence cholesterol. Centers for Disease Control and Prevention. https://www.cdc.gov/cholesterol/risk_factors.htm. 00 About 1 in 6 adult Americans has high Accessed November 16, 2017. cholesterol.2 2. Minino AM, Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2008. National Vital Statistics Reports. 00 Anyone can develop high cholesterol, 2011;59(10). https://www.cdc.gov/nchs/data/nvsr/nvsr59/ including children. nvsr59_10.pdf. 00 42.2% of US adults are at moderate risk of 3. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha developing high cholesterol, 13.1% are at MJ, Cushman M, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart high risk, and another 6.2% are thought to Association. Circulation. 2016;133(4):e38–60. be undiagnosed.3 4. Fox KM, Wang L, Gandra SR, Quek RGW, Li L, Baser O. Clinical and economic burden associated with cardiovascular events among patients with Cost of disease burden4 hyperlipidemia: a retrospective cohort study. BMC Cardiovasc Disord. 2016;16:13. 00 Among patients in the US with hyperlip- 5. Feingold KR, Brinton EA, Grunfeld C. The effect of idemia, the direct clinical and economic endocrine disorders on lipids and lipoproteins. [Updated 2017 Feb 24]. In: De Groot LJ, Chrousos G, Dungan K, annual costs associated with new cardio- Feingold KR, Grossman A, Hershman JM, et al., eds. vascular event (including up to 3 years Endotext [Internet]. South Dartmouth, MA: MDText. post-event) are approximately US$195.6 com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/ billion. NBK409608/. DYSLIPIDEMIA Overview Pathophysiology1 adipose tissue, and if in excess, depos- ited along artery walls. 00 No clear definition of dyslipidemia exists; ➤0 HDL particles can be protective against however, there is a linear relationship this process by removing cholesterol from between lipid levels and benefits of pharma- the artery walls and returning it to the cologic and non-pharmacologic treatments. liver; this is known as reverse cholesterol 00 A diagnosis of dyslipidemia can include any transport. (or a combination) of the following: 00 Atherosclerosis occurs as a compensatory ➤ 0 Elevated chylomicrons response to excess lipids, and this process is ➤ 0 Elevated triglycerides (TG) the basis of most acute coronary syndromes: ➤0 Elevated total cholesterol (TC) ➤0 LDL particles with a cholesterol and ➤ 0 Elevated low-density lipoproteins (LDL-C) triglyceride core enter the arterial wall. ➤ 0 Decreased high-density lipoproteins Macrophages consume these lipids and (HDL-C) trigger inflammation. 00 Cholesterol Transport and Removal2 ➤0 The resulting lipid core/macrophage ➤ 0 Chylomicrons take in dietary lipids in infiltration/inflammation is clinically the intestines, travel through the blood- referred to as plaque. stream, where muscle and adipose tissue ➤0 As the plaque grows, the arterial wall convert it into Chylomicron remnants. expands into the artery lumen. ➤0 Chylomicron remnants travel to the liver ➤0 Blood flow becomes progressively where they are converted into VLDL restricted and will continue to do so until particles. the artery becomes clotted off alto- ➤ 0 VLDL particles travel through the blood- gether, causing ischemia. stream where they are broken down ➤0 As plaques enlarge, they may burst, into a final product known as LDL parti- which allows the plaque components to cles and taken up into the muscles and enter the blood stream and cause full occlusions in smaller blood vessels. FIGURE 1: Excess lipids; Atherosclerosis Fatty Streak Formation Lipoprotein Oxidation Lipoproteins enter artery wall into intima Foam Cell Formation Bind to Decrease proteoglycan molecules that molecules maintain vascular Plaque Formation tome Monocytes are Increased recruited into production of intima, Maturation inflammatory differentiate into Foam cells markers (e.g., cell macrophages accumulate adhesion More oxidized Vascular wall molecules (CAM)) lipoproteins grows out into Lipid-rich core is accumulate arterial lumen formed Smooth muscle cells move from media to intima to form fibrous cap DYSLIPIDEMIA Etiology1 Early detection and screening1 Causes Should be Fasting lipoprotein profile should performed include the following: 00 Genetic mutation of receptors or every 5 ➤0 Total cholesterol (TC) apolipoproteins years on ➤0 Low-density lipoprotein (LDL-C; 00 Overproduction of lipids or beta-apolipo- adults 20 calculated) proteins (LDL) years of ➤0 High-density lipoprotein (HDL-C) 00 Underproduction of alpha-apolipoproteins age and ➤0 Triglycerides (TG) (HDL) older Non-HDL-C can be calculated by the Medications that can elevate following formula: non-HDL-C = TC – HDL-C LDL-C or TG3 LDL-C TG Both REFERENCES Anabolic Oral estrogen Cyclosporine 1. Talbert RL. Dyslipidemia. In: DiPiro JT, Talbert RL, Yee GC, steroids Matzke GR, Wells BG, Posey L. eds. Pharmacotherapy: A Tamoxifen, Thiazides Pathophysiologic Approach. 10th ed. New York, NY: Mc- Danazol Raloxifene Glucocorticoids Graw-Hill, 2017. 2. Feingold KR, Grunfeld C. Introduction to Lipids and Progestins Retinoids Thiazolidinedi- Lipoproteins. [Updated 2015 Jun 10]. In: De Groot LJ, Isotretinoin Sirolimus ones Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available Amiodarone Interferon (TG = from: https://www.ncbi.nlm.nih.gov/books/NBK305896/ rosiglitazone 3. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays Beta-blockers HE, Jones PH, et al. National Lipid Association only) recommendations for patient-centered management Atypical of dyslipidemia: part 1-full report. J Clin Lipidol. antipsychotics 2015;9(2):129–169. Protease inhibitors Fibrates or omega-3 Bile acid fatty acids (if sequestrants patient has L-asparaginase severely ele- Cyclophospha- vated TG and mide atherogenic dyslipidemia) DYSLIPIDEMIA Guidelines and Landmark Trials Guidelines 00 Jacobson T, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand, G, et al. 00 Stone NJ, Robinson J, Lichtenstein AH, National Lipid Association recommenda- Bairey Merz CN, Blum CB, Eckel RH, et al. tion for patient-centered management 2013 ACC/AHA guideline on the treatment of dyslipidemia: part 2. J Clin Lipidol. of blood cholesterol to reduce atheroscle- 2015;9(6):S1–S122.e1. rotic cardiovascular risk in adults. Circula- 00 Lloyd-Jones DM, Morris PM, Ballantyne CM, tion. 2014;129:S1–S45. Birtcher KK, Daly Jr DD, DePalma SM, et al. 00 Jacobson TA, Ito MK, Maki KC, Orringer 2017 focused update of the 2016 ACC expert CE, Bays HE, Jones PH, et al. National consensus decision pathway on the role of Lipid Association recommendations for non-statin therapies for LDL-cholesterol low- patient-centered management of dyslip- ering in the management of atherosclerotic idemia: part 1-full report. J Clin Lipidol. cardiovascular disease risk: a report of the 2015;9(2):129–169. American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017;70(14):1785–1822. Table 1: Guidelines for Hyperlipidemia Category Recommendation 2013 American Initiation of ➤0 Focus on prevention of atherosclerotic cardiovascular disease (ASCVD; eg, MI, angina, College of statin therapy stroke, PAD, revascularization). Cardiology/ ➤0 Recommend primary and secondary intervention in individuals without New York Heart American Association (NYHA) class II–IV heart failure and/or not receiving hemodialysis. Heart ➤0 Guideline organized by statin benefit groups. Association ➤0 Risk assessment conducted using Pooled Cohort Equations, which predicts a 10-year blood risk of ASCVD. cholesterol ➤0 No specific numeric goals of treatment, but rather proportional benefit is seen as com- guideline pared to the patient baseline. ➤0 In patients without clear indications, risk and benefit should be weighed for statin therapy. ➤0 Statin therapy is the only therapy recommended by this guideline owing to a lack of randomized controlled trials supporting other medications for reducing atherosclerotic cardiovascular disease and mortality. ➤0 Guideline recommends moderate- to high-intensity statins for most patients. Statin benefit ➤0 Patients ≥ 21 years of age for whom the ASCVD risk reduction clearly outweighs the risk groups of adverse events ➤0 Secondary prevention in individuals with clinical ASCVD ➤0 Primary prevention in individuals with LDL-C ≥ 190 mg/dL ➤0 Primary prevention in individuals with diabetes (but no ASCVD), 40 to 75 years of age, with LDL-C 70 to 189 mg/dL ➤0 Primary prevention in individuals 40 to 75 years of age with LDL-C 70 to 189 mg/dL without diabetes or ASCVD but with estimated 10-year ASCVD risk ≥ 7.5% Statin benefit ➤0 Primary prevention in individuals with 5–7.5% 10-year ASCVD risk and 40–75 years of group for age with LDL-C 70–89 mg/dL whom ➤0 < 5% 10-year ASCVD risk, or < 40 years old or > 75 years old moderate ➤0 Patients and providers should discuss ASCVD risk reduction benefits, adverse effects of evidence statin therapy, drug interactions, drug-disease interactions and patient preference. supports the use of statins DYSLIPIDEMIA Category Recommendation 2015 National Importance ➤0 Historically useful for both health care providers and patients to monitor progress.
Load more

Recommended publications
  • Anabolic Steroids/Androgens Pa Summary
    ANABOLIC STEROIDS/ANDROGENS PA SUMMARY PREFERRED Anadrol-50, Danazol, Fluoxymesterone, Methitest, Oxandrolone, Testosterone Cypionate Injection, Testosterone Enanthate Injection NON-PREFERRED Android, Testred LENGTH OF AUTHORIZATION: Varies NOTE: All preferred and non-preferred agents require prior authorization. See PA criteria labeled “Topical Testosterone” for Androderm, Androgel, Striant, and Testim. The criteria details below are for the outpatient pharmacy program. If an injectable medication is being administered in a physician’s office then the criteria information below does not apply. Instead, the physician’s office must bill this drug through the DCH physician’s injectable program and not the outpatient pharmacy program. Information regarding the physician’s injectable program can be located at www.mmis.georgia.gov. PA CRITERIA: For Anadrol-50 Approvable for the following diagnoses: anemia caused by deficient red blood cell production, acquired or congenital aplastic anemia, myelofibrosis, hypoplastic anemia due to administration of myelotoxic drugs Also approvable for HIV or AIDS wasting when significant weight loss is documented in members currently receiving nutritional support For Danazol Approvable for the following diagnoses: endometriosis, fibrocystic breast disease, hereditary angioedema For Fluoxymesterone, Methyltestosterone (Android, Methitest, Testred), Testosterone Cypionate or Enanthate Injection Approvable in male members 12 years of age or older for the following diagnoses: primary hypogonadism, secondary
    [Show full text]
  • Ep 2446888 A2
    (19) & (11) EP 2 446 888 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.05.2012 Bulletin 2012/18 A61K 31/569 (2006.01) (21) Application number: 11010272.0 (22) Date of filing: 12.07.2006 (84) Designated Contracting States: (71) Applicant: DMI Biosciences, Inc. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Englewood, CO 80110-3948 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (72) Inventor: Bar-Or, David Designated Extension States: Englewood, Colorado 80110 (US) AL BA HR MK RS (74) Representative: Schaeberle, Steffen (30) Priority: 12.07.2005 US 69872305 P Hoefer & Partner 24.08.2005 US 71115705 P Patentanwälte 24.08.2005 US 71115805 P Pilgersheimer Strasse 20 81543 München (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 06787393.5 / 1 919 290 This application was filed on 29-12-2011 as a divisional application to the application mentioned under INID code 62. (54) Use of danazol for the treatment of uveitis (57) The present invention relates to the treatment of an inflammatory disease or condition of the eye such as uveitis with danazof or a pharmacologically-acceptable salt or ester thereof. EP 2 446 888 A2 Printed by Jouve, 75001 PARIS (FR) EP 2 446 888 A2 Description FIELD OF THE INVENTION 5 [0001] The present invention relates to the treatment of diseases and conditions with an effective amount of a steroid having those formulas given below, or a pharmacologically-acceptable salt or ester thereof.
    [Show full text]
  • Hirsutism and Polycystic Ovary Syndrome (PCOS)
    Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients PATIENT INFORMATION SERIES Published by the American Society for Reproductive Medicine under the direction of the Patient Education Committee and the Publications Committee. No portion herein may be reproduced in any form without written permission. This booklet is in no way intended to replace, dictate or fully define evaluation and treatment by a qualified physician. It is intended solely as an aid for patients seeking general information on issues in reproductive medicine. Copyright © 2016 by the American Society for Reproductive Medicine AMERICAN SOCIETY FOR REPRODUCTIVE MEDICINE Hirsutism and Polycystic Ovary Syndrome (PCOS) A Guide for Patients Revised 2016 A glossary of italicized words is located at the end of this booklet. INTRODUCTION Hirsutism is the excessive growth of facial or body hair on women. Hirsutism can be seen as coarse, dark hair that may appear on the face, chest, abdomen, back, upper arms, or upper legs. Hirsutism is a symptom of medical disorders associated with the hormones called androgens. Polycystic ovary syndrome (PCOS), in which the ovaries produce excessive amounts of androgens, is the most common cause of hirsutism and may affect up to 10% of women. Hirsutism is very common and often improves with medical management. Prompt medical attention is important because delaying treatment makes the treatment more difficult and may have long-term health consequences. OVERVIEW OF NORMAL HAIR GROWTH Understanding the process of normal hair growth will help you understand hirsutism. Each hair grows from a follicle deep in your skin. As long as these follicles are not completely destroyed, hair will continue to grow even if the shaft, which is the part of the hair that appears above the skin, is plucked or removed.
    [Show full text]
  • WO 2013/163758 Al 7 November 2013 (07.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2013/163758 Al 7 November 2013 (07.11.2013) P O P C T (51) International Patent Classification: (72) Inventor; and A61K 31/416 (2006.01) C12Q 1/00 (2006.01) (71) Applicant : BOYD, Shelley Romayne [CA/CA]; Unit A61P 27/02 (2006.01) A61B 3/10 (2006.01) 2106, 112 George Street, Toronto, Ontario M5A 2M5 (CA). (21) International Application Number: PCT/CA2013/050335 (74) Agents: MARLES, Jennifer A. et al; 480-601 West Cor dova Street, Vancouver, British Columbia V6B 1G1 (CA). (22) International Filing Date: 30 April 2013 (30.04.2013) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 61/640,854 1 May 2012 (01.05.2012) US KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 61/641,393 2 May 2012 (02.05.2012) US ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/693,226 24 August 2012 (24.08.2012) us NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 61/792,436 15 March 2013 (15.03.2013) us RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Endometriosis
    CLINICAL REVIEW Endometriosis Follow the link from the online version of this article to obtain certi ed continuing 1 2 3 medical education credits Martha Hickey, Karen Ballard, Cindy Farquhar 1 Endometriosis is a relatively common and potentially Department of Obstetrics and SOURCES AND SELECTION CRITERIA Gynaecology, University of debilitating condition affecting women of reproductive We searched Medline and Pubmed, used personal archives Melbourne and the Royal Women’s age. Prevalence is difficult to determine, firstly because of Hospital, Melbourne, Victoria, of references, and consulted with other experts to inform Australia 3052 variability in clinical presentation, and, secondly because this manuscript. When available, data from systematic 2Faculty of Health and Medical the only reliable diagnostic test is laparoscopy, when endo- reviews and randomised controlled trials were used. We Sciences, University of Surrey, metriotic deposits can be visualised and histologically also used expert guidelines such as the recent European Guildford, Surrey, UK Society of Human Reproduction and Embryology (ESHRE) 3 confirmed. Population based studies report a prevalence Department of Obstetrics and consensus.4 Gynaecology, University of of around 1.5% compared with 6-15% in hospital based 1 Auckland, Auckland, New Zealand studies. Endometriosis can be asymptomatic, but those Correspondence to: M Hickey with symptoms generally present early in reproductive What are the causes of endometriosis? [email protected] life and improve after menopause. Symptomatic endome- The pathogenesis of endometriosis is unknown, but lead- Cite this as: BMJ 2104;348:g1752 triosis can result in long term adverse effects on personal ing theories include retrograde menstruation, altered doi: 10.1136/bmj.g1752 relationships, quality of life, and work productivity.
    [Show full text]
  • Effects of Androgenic-Anabolic Steroids on Apolipoproteins and Lipoprotein (A) F Hartgens, G Rietjens, H a Keizer, H Kuipers, B H R Wolffenbuttel
    253 ORIGINAL ARTICLE Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a) F Hartgens, G Rietjens, H A Keizer, H Kuipers, B H R Wolffenbuttel ............................................................................................................................... Br J Sports Med 2004;38:253–259. doi: 10.1136/bjsm.2003.000199 Objectives: To investigate the effects of two different regimens of androgenic-anabolic steroid (AAS) administration on serum lipid and lipoproteins, and recovery of these variables after drug cessation, as indicators of the risk for cardiovascular disease in healthy male strength athletes. Methods: In a non-blinded study (study 1) serum lipoproteins and lipids were assessed in 19 subjects who self administered AASs for eight or 14 weeks, and in 16 non-using volunteers. In a randomised double blind, placebo controlled design, the effects of intramuscular administration of nandrolone decanoate (200 mg/week) for eight weeks on the same variables in 16 bodybuilders were studied (study 2). Fasting serum concentrations of total cholesterol, triglycerides, HDL-cholesterol (HDL-C), HDL2-cholesterol (HDL2- C), HDL3-cholesterol (HDL3-C), apolipoprotein A1 (Apo-A1), apolipoprotein B (Apo-B), and lipoprotein (a) (Lp(a)) were determined. Results: In study 1 AAS administration led to decreases in serum concentrations of HDL-C (from 1.08 (0.30) to 0.43 (0.22) mmol/l), HDL2-C (from 0.21 (0.18) to 0.05 (0.03) mmol/l), HDL3-C (from 0.87 (0.24) to 0.40 (0.20) mmol/l, and Apo-A1 (from 1.41 (0.27) to 0.71 (0.34) g/l), whereas Apo-B increased from 0.96 (0.13) to 1.32 (0.28) g/l.
    [Show full text]
  • The Realization of New Medical Alternatives to Surgery for Endometriosis
    Paradigm Shift: The Realization of New Medical Alternatives to Surgery for Endometriosis Edward M. Lichten, MD* ©2016, Edward M. Lichten, MD Journal Compilation ©2016, AARM DOI 10.14200/jrm.2016.5.0099 ABSTRACT Endometriosis is one of the most destructive benign diseases of women. It is established as developing and being present in upward of 70% of adolescents who do not experience relief of menstrual pain with use of oral contraceptives and anti- inflammatory drugs. It occurs in 8%–10% of women in the United States and is most prevalent in developed countries. Symptoms of endometriosis include disabling pain, hemorrhagic uterine bleeding, and infertility. Women with disease can expect a 12% hysterectomy rate. While present medical therapy may offer relief of many symptoms, there have been no major new directions in pharmacologic therapy since leuprolide acetate was made available in 1977. Danazol remains the only alternative to GnRH agonists with proven efficacy and reasonable side effects, according to Cochrane Reviews, yet, it is underused, and GnRH agonists are favored even when Danazol in combination seems more effective. A previously published case report on use of the combination of nandrolone and stanozolol to treat a young woman scheduled for hemicolectomy is discussed as an alternative to surgery along with the limits of standard therapy. This review will focus on recent research and theories seeking to establish causation for disease and offer treatment recommendations. Keywords: Endometriosis; Environmental toxins; Xenoestrogens;
    [Show full text]
  • Synthetic Steroid Hormones Regulated Cell Proliferation Through Microrna-34A-5P in Human Ovarian Endometrioma1
    BIOLOGY OF REPRODUCTION (2016) 94(3):60, 1–10 Published online before print 27 January 2016. DOI 10.1095/biolreprod.115.133330 Synthetic Steroid Hormones Regulated Cell Proliferation Through MicroRNA-34a-5p in Human Ovarian Endometrioma1 Chia-Yi Hsu,3 Tsung-Hua Hsieh,4 Cheng-Fang Tsai,3 Hung-Sheng Chen,4 Peir-In Liang,5 Ya-Ling Hsu,3 and Eing-Mei Tsai2,3,4,6 3Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung City, Taiwan 4Department of Obstetrics and Gynecology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Downloaded from https://academic.oup.com/biolreprod/article/94/3/60, 1-10/2434415 by guest on 24 September 2021 Kaohsiung City, Taiwan 5Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan 6Center for Research Resources and Development, Kaohsiung Medical University, Kaohsiung City, Taiwan ABSTRACT steroid hormones and suggest a potential mechanism for endometriosis treatment. Endometriosis is the hormone-dependent product of endo- metrial tissue found outside the uterus. Recently, micro-RNAs danazol, endometrial mesenchymal stem cells, medroxypro- (miRNAs) were shown to play a role in endometriotic lesion gesterone acetate, progesterone development. However, the mechanism of steroid hormones Downloaded from www.biolreprod.org. responsible for miRNA remains obscure. In the present study, INTRODUCTION we assayed for the effects of synthetic steroid hormones Endometriosis, defined as the presence of endometriallike (danazol, progesterone, and medroxyprogesterone acetate tissue outside the uterus, is a common estrogen-dependent [MPA]) on miRNAs in endometriosis. We used a global miRNA gynecological disorder with a complex, multifactorial etiology expression profile microarray to evaluate miRNA expression in that affects approximately 10%–15% of women of reproduc- endometrial mesenchymal stem cells (EN-MSCs) of ovarian tive age.
    [Show full text]
  • Hepatotoxicity by Dietary Supplements: a Tabular Listing and Clinical Characteristics
    International Journal of Molecular Sciences Review Hepatotoxicity by Dietary Supplements: A Tabular Listing and Clinical Characteristics Miren García-Cortés 1,2,†, Mercedes Robles-Díaz 1,2,*,†, Aida Ortega-Alonso 1, Inmaculada Medina-Caliz 1 and Raul J. Andrade 1,2 1 Servicio de Farmacología Clíınica and Unidad de Gestión Clínica (UGC) de Gastroenterología y Hepatología, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga (UMA), 29010 Málaga, Spain; [email protected] (M.G.-C.); [email protected] (A.O.-A.); [email protected] (I.M.-C.); [email protected] (R.J.A.) 2 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain * Corresponding: [email protected]; Tel.: +34-95-213-6647 † These authors contributed equally to this work. Academic Editor: Igor P. Pogribny Received: 22 February 2016; Accepted: 25 March 2016; Published: 9 April 2016 Abstract: Dietary supplements (DS) are extensively consumed worldwide despite unproven efficacy. The true incidence of DS-induced liver injury (DSILI) is unknown but is probably under-diagnosed due to the general belief of safety of these products. Reported cases of herbals and DS-induced liver injury are increasing worldwide. The aim of this manuscript is to report a tabular listing with a description of DS associated with hepatotoxicity as well as review the phenotype and severity of DSILI. Natural remedies related to hepatotoxicity can be divided into herbal product-induced liver injury and DS-induced liver injury. In this article, we describe different DS associated with liver injury, some of them manufactured DS containing several ingredients (Herbalife™ products, Hydroxycut™, LipoKinetix™, UCP-1 and OxyELITE™) while others have a single ingredient (green tea extract, linoleic acid, usnic acid, 1,3-Dimethylamylamine, vitamin A, Garcinia cambogia and ma huang).
    [Show full text]
  • Breast Pain AMIT GOYAL, Royal Derby Hospital, Derby, United Kingdom
    Clinical Evidence Handbook A Publication of BMJ Publishing Group Breast Pain AMIT GOYAL, Royal Derby Hospital, Derby, United Kingdom This is one in a series of Breast pain (mastalgia) may be cyclic (worse a first-line treatment, as the benefits are chapters excerpted from before a period) or noncyclic, originating thought to outweigh the risk of adverse the Clinical Evidence Handbook, published by from the breast or the chest wall, and occurs effects. the BMJ Publishing Group, at some time in 70% of women. We found insufficient evidence to assess London, U.K. The medical Cyclic breast pain resolves spontane- the effects of oral NSAIDs on breast pain. information contained • herein is the most accurate ously in 20% to 30% of women but We do not know whether topical NSAIDs available at the date of tends to recur in up to 60% of women. are more effective than oral NSAIDs at publication. More updated • Noncyclic pain responds poorly to treat- reducing breast pain. and comprehensive infor- ment but tends to resolve spontaneously Danazol, tamoxifen, and gonadorelin mation on this topic may be available in future print in about one-half of women. analogues (goserelin) may reduce breast editions of the Clinical Evi- • An accurate diagnosis of true breast pain, but all can cause adverse effects. These dence Handbook, as well pain should be made, and other non- agents would usually be prescribed only by a as online at http://www. breast pathology should be excluded. subspecialist. clinicalevidence.bmj.com (subscription required). The differential diagnosis includes pain • Danazol can cause weight gain, deepen- arising from the chest wall.
    [Show full text]
  • A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector ORIGINAL ARTICLE A Randomized, Parallel, Comparative Study of the Efficacy and Safety of Nafarelin Versus Danazol in the Treatment of Endometriosis in Taiwan Ming-Huei Cheng1,2, Bill Ken-Jen Yu1–4, Sheng-Ping Chang1,2, Peng-Hui Wang1,2* 1Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 2National Yang-Ming University School of Medicine, 3Department of Obstetrics and Gynecology, Taipei City Hospital, and 4National Defense Medical Center, Taipei, Taiwan, R.O.C. Background: The purpose of this study was to evaluate the efficacy and safety of nafarelin, a gonadotropin-releasing hormone (GnRH) analogue, versus danazol in the treatment of women with endometriosis in Taiwan. Methods: Fifty-nine women with laparoscopically and pathologically confirmed endometriosis were randomized to receive nafarelin or danazol for 180 days. Efficacy was assessed from mean changes in laparoscopy score (LS) and total symptom severity score (TSSS). Adverse events (AEs) and laboratory parameters, including hematology, hepatic function, blood pressure, and lipid levels, were monitored for safety evaluations. Results: All demographic and baseline factors, except body weight, were comparable between the 2 treatment groups. Both nafarelin and danazol satisfactorily resolved pelvic tenderness, induration, pelvic pain, dysmenorrhea and dyspareunia. No significant differences were noted in efficacy endpoints between nafarelin and danazol regarding LS and TSSS at 90 and 180 days of treatment. No significant difference was observed between the 2 groups regarding the overall incidence of AEs, except for laboratory-related AEs. However, nafarelin tended to have less impact than danazol on aspartate transaminase and alanine transaminase, and nafarelin was better tolerated than danazol regarding changes in lipid profiles.
    [Show full text]
  • Myocardial Infarction in Irradiated Rats
    BIOCHEMICAL STUDY ON THE PROTECTIVE EFFECT OF ANTIOXIDANT AND β-ADRENERGIC BLOCKING AGENT AGAINST EXPERIMENTAL MYOCARDIAL INFARCTION IN IRRADIATED RATS Ph.D. Presented by Hanan Fahmy Abdel-Hamied Assistant lecturer Drug Radiation Research Department National Center for Radiation Research and Technology (NCRRT) Atomic Energy Authority For the Degree OF Doctor of Philosophy in Pharmaceutical sciences (Biochemistry) Under The Supervision of Prof. Dr Ola Sayed M. Ali Prof. Dr. Seham Hassan Mohamed Professor of Biochemistry Professor of Vice Dean of Pharmacology&Toxicology Faculty of Pharmacy (Girls) Vice Chairman of the Biotechnology Al-Azhar University Sector (NCRRT) Atomic Energy Authority Dr. Ragia Ali Taha Assistant Professor of Pharmacology Faculty of pharmacy (Girls) AL-Azhar University Faculty of Pharmacy (Girls) Al- Azhar University (2009) ACKNOWLEDGMENT First and foremost thanks to Allah, the most merciful for guiding and giving me the strength to complete this work. My sincere thanks and gratitude to Prof. Dr. Ola Sayed , Vice Dean & prof. of Biochemistry, faculty of pharmacy (Girls), A- Azhar University for her keen supervision, valuable advice, great support and sincere help throughout this thesis. My cordial thanks and appreciation are given to Prof. Dr. Seham Hassan vice chairman of biotechnology sector & Prof. of Pharmacology & Toxicology, (NCRRT), Atomic Energy Authority, Cairo, for suggesting the point, keen supervision, expert advice and for her help in carrying out experimental investigation, writing, reviewing the thesis and for her kind help to overcome many of the difficulties that arose in the course of this research. I am also grateful to Dr. Ragia Taha Assistant Prof. of pharmacology, faculty of pharmacy (Girls), Al- Azhar University .for her kind supervision, encouragement and support throughout revising this thesis.
    [Show full text]